GlobeNewsWire
17 Mar 2026, 18:45 UTC · 27w ago
Verdict
Headline leans bearish. We score ALDX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter for Aldeyra Therapeutics' reproxalap, stating the product failed to demonstrate efficacy in clinical trials for dry eye disease.
So whatA failure to gain FDA approval for a primary drug candidate is a catastrophic event for a biotech company's valuation.
More negative than 99% of claims this week
Aldeyra Therapeutics shares fell over 65% in trading on March 17, 2026, following the FDA disclosure.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
Law firm Block & Leviton is investigating Aldeyra Therapeutics for potential securities law violations.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is being investigated for securities fraud following a 65% stock price drop and FDA rejection of its drug reproxalap.
More negative than 85% of ticker scores this week
The company is under investigation by Block & Leviton for potentially misleading investors.
More negative than 85% of ticker scores this week
The company is being investigated by Block & Leviton for possible securities fraud.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
50m ago
−71.5%
Price agrees with the score
$1.21 vs $4.23 close before publication (Mar 16) · not market-adjusted
ALDX chart →
